Due to the associations between high MDSC infiltrates and therapy resistance across cancer types [7], tumors with high levels of MDSCs or patients who have developed resistance to prior lines of therapy may benefit from treatment with a CXCR2 antagonist. This evidence concerns the gene CXCR2 and cancer.